Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹12,536 Cr
Revenue (TTM)
₹2,089 Cr
Net Profit (TTM)
₹614 Cr
ROE
21.7 %
ROCE
26.2 %
P/E Ratio
20.4
P/B Ratio
3.8
Industry P/E
28.7
EV/EBITDA
14.2
Div. Yield
0.4 %
Debt to Equity
0
Book Value
₹437.5
EPS
₹80.7
Face value
2
Shares outstanding
76,011,696
CFO
₹1,981.95 Cr
EBITDA
₹3,293.63 Cr
Net Profit
₹2,658.05 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Caplin Point Lab
| -10.3 | -4.3 | -13.2 | -10.9 | 39.2 | 30.2 | 23.4 |
|
BSE Healthcare
| -1.7 | -1.1 | -1.9 | 7.5 | 25.6 | 15.6 | 10.7 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Caplin Point Lab
| -26.8 | 84.4 | 90.1 | -16.9 | 69.9 | 71.9 | -21.4 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Caplin Point Lab
|
1,648.2 | 12,536.2 | 2,089.5 | 622.0 | 31.3 | 20.4 | 20.4 | 3.8 |
| 3,056.6 | 38,176.6 | 5,201.6 | 1,014.6 | 22.9 | 25 | 37.6 | 8.3 | |
| 8,483.5 | 21,239.3 | 2,177.5 | 200.9 | 11.3 | 26.5 | 105.7 | 25.5 | |
| 1,308.1 | 18,156.7 | 3,078.2 | 469.4 | 26.4 | 14.9 | 42.1 | 5.0 | |
| 2,118.0 | 33,968.6 | 4,193.0 | 753.8 | 22.7 | 20.8 | 45.1 | 8.5 | |
| 4,818.0 | 22,063.4 | 2,482.3 | 853.6 | 33.7 | 18.9 | 25.8 | 5.5 | |
| 4,939.8 | 8,194.5 | 1,348.5 | 293.5 | 28.1 | 50.7 | 27.9 | 11.8 | |
| 3,460.8 | 7,974.5 | 1,837.4 | 326.7 | 24.7 | 45.3 | 24.4 | 10.6 | |
| 324.6 | 6,348.6 | 1,432.0 | 149.0 | 19.1 | 7.9 | 42.3 | 2.5 | |
| 907.1 | 8,342.6 | 4,725.6 | 528.7 | 14.9 | 20.7 | 16.3 | 2.8 |
Companies with less institutional holdings
4 min read•By Jugal Harpalani
2 min read•By Jugal Harpalani
5 min read•By Rajan Gulati
Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India. The company provides tablets, capsules, injections,... ophthalmic, liquid orals, softgel capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag formulations, inhalers, and sprays and IV infusion. It also provides dry syrups, lyophilized vials, prefilled syringes, emulsion injection, and topicals. Caplin Point Laboratories Limited was incorporated in 1990 and is headquartered in Chennai, India. Read more
Incorporated
1990
Chairman
C C Paarthipan
Managing Director
Sridhar Ganesan
Headquarters
Chennai, Tamil Nadu
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Caplin Point Laboratories Ltd is ₹1,648.20 (NSE) and ₹1,649.25 (BSE) as of 18-Mar-2026 IST. Caplin Point Laboratories Ltd has given a return of 39.24% in the last 3 years.
The P/E ratio of Caplin Point Laboratories Ltd is 20.43 times as on 18-Mar-2026, a 29 discount to its peers’ median range of 28.70 times.
The P/B ratio of Caplin Point Laboratories Ltd is 3.77 times as on 18-Mar-2026, a 18 discount to its peers’ median range of 4.57 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
28.38
|
5.52
|
|
2024
|
21.89
|
4.49
|
|
2023
|
12.04
|
2.53
|
|
2022
|
17.19
|
3.70
|
|
2021
|
12.62
|
2.79
|
The 52-week high and low of Caplin Point Laboratories Ltd are Rs 2,395.00 and Rs 1,599.00 as of 19-Mar-2026.
Caplin Point Laboratories Ltd has a market capitalisation of ₹ 12,536 Cr as on 18-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Caplin Point Laboratories Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹13.10
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.